Azurity’s Acquisition of Arbor Pharmaceuticals

Wilson Sonsini Goodrich & Rosati and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Azurity on the deal while King & Spalding represented Arbor Pharmaceuticals.

Azurity Pharmaceuticals, Inc. and Arbor Pharmaceuticals, Inc. have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR. Following the completion of the transaction, which is subject to regulatory approvals, Azurity and Arbor will merge, creating a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions. Financial details of the transaction were not disclosed.

A Wilson Sonsini Goodrich & Rosati team that advised Azurity on IP and litigation matters related to this transaction included: Samir Elamrani (Picture), Wendy Devine, Clark Lin, Ying Chen, Sherrie Holdman, Johnson Truong, Rida Atif and Joseph Lesniewski.

The King & Spalding deal team is led by Rahul Patel and John Anderson, and includes Nik Patel and Umbar Malik. Additional assistance was provide by Kevin Michael Smith, John K. Sweet, Jessica M. Stricklin, Robert J. Leclerc (Rob), Derek B. Meilman, Albert Y Kim, Jessica Ringel, Shane Dornburg, Natalie R. Whitaker, Conrad C Axelrod, Matthew A. Krimski, Brian R. Meiners, Ruoxi Zhang, Zachary J. Davis, Les Oakes, Jean Cogill (Jeanie), John H. Fontham (Jack), Amanda A. Sonneborn, Jake Downing, Nikki Reeves and Keith M. Townsend.

The Smith Anderson legal team advising Azurity in the merger was led by attorneys Byron Kirkland, Justin Truesdale, James Jolley and Will Robinson and was a collaborative effort with support from the firm’s Private Equity practice group, including Miranda Miller, and the firm’s Finance team, including Bart Norman and Tricia McNeill.

Involved fees earner: John Anderson – King & Spalding; Conrad Axelrod – King & Spalding; Jean Cogill – King & Spalding; Zachary Davis – King & Spalding; Shane Dornburg – King & Spalding; Jake Downing – King & Spalding; John Fontham – King & Spalding; Albert Kim – King & Spalding; Matthew Krimski – King & Spalding; Robert Leclerc – King & Spalding; Derek Meilman – King & Spalding; Brian Meiners – King & Spalding; Les Oakes – King & Spalding; Rahul Patel – King & Spalding; Nikki Reeves – King & Spalding; Jessica Ringel – King & Spalding; Kevin Michael Smith – King & Spalding; Amanda Sonneborn – King & Spalding; Jessica Stricklin – King & Spalding; John Sweet – King & Spalding; Keith Townsend – King & Spalding; Natalie Whitaker – King & Spalding; Ruoxi Zhang – King & Spalding; James Jolley – Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan; Byron Kirkland – Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan; Miranda Miller – Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan; Bart Norman – Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan; William Robinson – Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan; Justin Truesdale – Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan; Rida Atif – Wilson Sonsini Goodrich & Rosati; Ying Chen – Wilson Sonsini Goodrich & Rosati; Wendy Devine – Wilson Sonsini Goodrich & Rosati; Samir Elamrani – Wilson Sonsini Goodrich & Rosati; Sherrie Holdman – Wilson Sonsini Goodrich & Rosati; Joseph Lesniewski – Wilson Sonsini Goodrich & Rosati; Clark Lin – Wilson Sonsini Goodrich & Rosati; Johnson Truong – Wilson Sonsini Goodrich & Rosati;

Law Firms: King & Spalding; Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan; Wilson Sonsini Goodrich & Rosati;

Clients: Arbor Pharmaceuticals LLP; Azurity Pharmaceuticals;

Martina Bellini

Author: Martina Bellini